Navigation Links
For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe
Date:12/15/2009

WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

The new Special European Physician & Payer Forum report entitled European Trends in Targeted Therapies in Breast Cancer: A Clinician and Payer Perspective on the Current and Future Uptake finds that, despite not having a HER2 (human epidermal growth factor receptor-2) status label restriction in Europe, most surveyed oncologists reserve Avastin for HER2-negative patients, particularly for patients with triple negative breast cancer. Avastin is at risk of losing significant patient share to Sanofi-Aventis' novel agent BSI-201, which is expected to be approved for triple negative breast cancer on the basis of an improvement in overall survival.

According to the report, in the surveyed European countries where Avastin is reimbursed, Avastin is used in between 16 percent (in Italy) and 38 percent (in France) of first-line metastatic breast cancer patients and between 8 percent (in Italy) and 27 percent (in France) of second-line metastatic breast cancer patients. Through 2010, Avastin's patient share will increase to between 25 percent (in Italy and Spain) and 35 percent (in France) in the first-line treatment setting and between 17 percent (in Italy) and 36 percent (in France) in the second-line. This equates to a potential 30 percent increase in Avastin sales over the next 12 months.

The report also finds that reimbursement of targeted therapies for breast cancer varies significantly between the European countries surveyed.

"Among the four major European markets that reimburse Avastin--Germany, France, Italy a
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... supplier of injectable drug delivery systems, today announced ... and facilities in response to increasing demand from ... services. During the fourth quarter of fiscal year ... capital expenditures and R&D above normal quarterly investments. ...
(Date:7/30/2014)... N.Y. , July 30, 2014 /PRNewswire-iReach/ -- ... -based medical device company, has announced today ... the velox CD™ Vascular Closure Device. Velox CD™ ... immediate hemostasis following percutaneous femoral procedures. The single ... broadly ranging in size from 5F to 8F.  ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... SIRO Clinpharm a leading Contract Research Organization (CRO) based out ... Nimita Limaye, PhD, SIRO Vice President and Global Head, Strategic Data ... the Society for Clinical Data Management (SCDM).   "I ... I hope that I will live up to the ...
... At this year,s Annual Meeting of the American ... (NYSE: PHG, AEX: PHI) is demonstrating how the ... simplify the clinician and patient experience. ... http://www.newscom.com/cgi-bin/prnh/20091127/NY17547LOGO ) Specially designed ...
Cached Medicine Technology:SIRO Clinpharm's Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM) 2Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 2Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 3Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 4
(Date:7/30/2014)... July 31, 2014 “United States Orthopedic Braces ... on the United States Orthopedic Braces and Supports market. The ... (in units) and average price data (in US dollars), within ... , Ankle Braces and Supports , ... and Supports. , Orthotics is a specialty within ...
(Date:7/30/2014)... 30, 2014 Daily Gossip mentions that the ... an effective way to stop anxiety and eliminate all associated ... helped no less than 150,000 people in getting their lives ... a complex anxiety treatment system that will teach sufferers different ... method is very simple to access, as it is available ...
(Date:7/30/2014)... 30, 2014 Ticket Down is ... Munich vs. Chivas Guadalajara friendly exhibition match at the ... Cup, the one team that was left standing as the ... it through the world’s largest football competition and even embarrassed ... way to the cup. Germany was led by seven players ...
(Date:7/30/2014)... education in sub-Saharan Africa is being revitalized and ... increasing enrollment, broadening curricula, upgrading Internet access and ... , In the first substantial publication by participants ... (MEPI), more than 225 authors detailed progress being ... in a supplement being published today by the ...
(Date:7/30/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... United States, at least 2,000 Americans die from extreme heat ... Heat waves, heat stroke or sun stroke caused nearly one-third ... 2010, according to the U.S. Centers for Disease Control and ... of body heat -- accounted for 63 percent of those ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:Panic Away Review Reveals How to Stop Anxiety 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3
... ... improved risk management and visibility at the management and board level , ... MetricStream, Inc., the market ... entered into an agreement with AEI, an emerging markets energy infrastructure company, to provide ...
... pressure monitoring (HBPM) program supported by the American Heart ... for patients with uncontrolled hypertension, according to a study. ... 18 to 85 years, and with Internet access were ... HBPM group. All patients had their blood pressure measured ...
... in or drive them away , FRIDAY, May 21 (HealthDay ... taste, two new studies reveal that harmonic arrangements and rhythm ... or drive them away. , The first study, from the ... of Current Biology , found that the musical chords ...
... ... in 2010; Allsup outlines 10 reasons to get SSDI representation, , ... Belleville, IL (Vocus) May 21, 2010 ... mark five times already by April. As millions of people inundate the agency, it’s ...
... , ... Water Enabled Technologies, LLC, Salt Lake City, Utah and Clemson University, Clemson, South ... a new process for desalination and with Clemson University will develop existing and ... water at a fraction of the energy currently required by RO or Evaboration ...
... ... against wrinkles -- up its sleeve. Make sure you tune in as we team up ... ... The Balancing Act just might have a secret weapon – against wrinkles -- up its sleeve. ...
Cached Medicine News:Health News:MetricStream Enters into Agreement to Provide Enterprise Risk Management Software Solution to AEI 2Health News:The Science Behind Musical Taste 2Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 2Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 3Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 4Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 5Health News:Water Enabled Technologies of Utah Signs MOU with Clemson University, South Carolina, for Water Desalination 2Health News:O2 Media's Hit Morning TV Show ‘The Balancing Act' Welcomes Absolute Miracle Cream to the Program 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The "three-in-one Microkeratome for traditional Lasik, Epi-Lasik ... a world of rapidly changing technologies and ... II is and remains a proven value, ... their needs and allows them to stay ...
Medicine Products: